现场，比尔及梅琳达·盖茨基金会疫苗开发小组主任Anita Zaidi博士，帕斯适宜卫生科技组织（PATH）基本药物副总裁、疫苗创新和可及性中心负责人David Kaslow博士，前英国国家生物制品检定所（NIBSC）副所长Philip Minor博士，全球疫苗免疫联盟(GAVI)总裁Seth Berkley博士等也专门录制了视频，为会议的举办送上寄语，并对中国在此次疫情防控中的表现和贡献给予肯定。
盖茨基金会疫苗开发部主任Anita Zaidi博士表示，很高兴看到中国在新冠疫苗研发方面作出的重大努力和投入，中国的研究人员已经建立了包含多种疫苗路线的研发管线，这体现了中国公共与私营部门一起应对这一全球巨大挑战的坚定承诺。Anita Zaidi博士指出，盖茨基金会支持中国的合作伙伴应对此次大流行病挑战，会共同开发和部署疫苗、药物和诊断试剂来为全球提供帮助。
1、ag龙虎厅 - 首页
Strengthen vaccine protection
Join hands with the global fight against the epidemic
They have issued important initiatives!
On the evening of May 18, At the opening ceremony of the 73rd World Health Assembly video conference, President Xi Jinping delivered a speech entitled "Unity and Cooperation to Overcome the Epidemic and Build a Human Health Community", In his speech, he announced whenever the COVID-19 Vaccine finishes its R&D phase and put into use, it will serve as a global public product and make China's contribution to the accessibility and affordability of vaccines in developing countries.
In order to speed up the research and development of COVID-19 Vaccine and strengthen technological innovation and cooperation in the vaccine field, the second meeting of the China Vaccine Industry Technological Innovation Strategic Alliance was held in Beijing on May 18 (hereinafter referred to as the "Vaccine Alliance").
Sun Yanrong, Deputy Director, and Lu Shan, Deputy department Chief of the China National Center for Biotechnology Development of the Ministry of Science and Technology attended the meeting. Wu Zhiyin, director of the Vaccine research and development committee for COVID-19 Prevention and Control and the Joint Prevention and Control Mechanism of the State Council was invited as a distinguished guest to attend the meeting for guidance. Institutions from China's vaccine research and development, production, supervision and application fields, including government departments, scientific research institutes, universities, production enterprises and other 27 governing bodies, a total of more than 60 people attended the meeting on site and remotely.
Yang Xiaoming, chairman of the Vaccine Alliance and chairman of China National Biotec Company Group, delivered an opening remarks on behalf of the Alliance. He pointed out that with the outbreak and prevalence of COVID-19 infection, global public health safety is facing severe challenges and tests. Rapid emergency response and successful development of vaccines have become urgent tasks at present and in the future. Vaccines are the most economical and effective means to prevent and control infectious diseases, and are also important means to carry out biological safety protection and safeguard national security. At present, the prevention and control of the epidemic situation has changed from an emergency state to normalization. The current primary task is to fully protect people's lives, health and safety and fully restore social and economic order. Vaccines are the fundamental measure to accomplish this task. China is one of the few countries in the world that can rely on its own capabilities to solve the problem of immunization supply and vaccination. At present, China can cope with most infectious diseases that are harmful to the population and highly infectious. A vaccine application research and industrial development system was also built up a preliminary form, but there is still a certain gap from the target. Today, the number of governing units of the Vaccine Alliance has increased from 14 to 27, which is the mainstay of the development of China's vaccine industry. At this critical moment in the global fight against the epidemic, he suggests experts attending the meeting to actively offer suggestions and advices on how to achieve the ultimate goal of epidemic prevention and control, complete the task and mission of China's vaccine industry, and jointly fight the epidemic with global counterparts, produce vaccine as early as possible and as good as possible, guarantee supply and promote application and R&D, strengthen the development of China's vaccine industry and promote international cooperation against the epidemic.
Sun Yanrong, Deputy Director of the China National Center for Biotechnology Development of the Ministry of Science and Technology, said in her speech that science and technology are the most powerful weapon to overcome the COVID-19 epidemic. It can provide strong support to return life to normal. She talked about her feelings with several words featured by"100". First, in the past 100 years, China's vaccine products industry has gone through a 100-year development process. People have changed from passive immunization to active immunization, achieving a substantial increase in life expectancy. The second is 100 days. In the more than 100 days since the outbreak of the epidemic, more than a dozen scientific research teams in China have gone all out to develop vaccines day and night, not only fast but also good. It is precisely because of their efforts that we have made, five research and development teams' vaccines have entered the clinical trial stage today. Third are 100 people. In this scientific research, our country has laid out 5 vaccine research and development technical routes and 12 research and development teams. In addition, we still have 100 backbone personnel and 100 technicians working hard, which shows us the hope of getting out of the strait and overcoming the epidemic. Fourth are 100 projects. At present, more than 100 products are being developed around the world. We have seen the joint efforts of scientists around the world and the selfless dedication of entrepreneurs, contributing to the global war against epidemic. The fifth is score 100. I believe that the accumulation and precipitation of our vaccine industry over the past 100 years can really make new contributions to the development of safe and effective vaccines, prevent and control global epidemics, and protect of the life and health of all mankind.
In his speech, Director Wu Zhiyin of the Vaccine research and development committee for COVID-19 Prevention and Control and the Joint Prevention and Control Mechanism of the State Council pointed out that vaccines are the "ballast stones" for the global fight against the new crown epidemic. At present, important progress has been made in the research and development of the COVID-19 vaccine. He thanked all scientific research teams for their efforts in the research and development of the COVID-19 vaccine. However, vaccine research and development cannot be slackened at all. All scientific research teams should improve their strategic layout, focus on the future, work together, accelerate research and development, and strive for the early marketing of the COVID-19 vaccine.
Zhang Yuntao, vice president of China National Biotec Company Group, introduced the establishment of the vaccine alliance, its tasks and responsibilities, systematically introduced the research and development progress of the COVID-19 vaccine at home and abroad, and made a forecast and judgment on the future development of COVID-19 vaccine.
At the scene, Dr. Anita Zaidi, Director of the Vaccine Development Team of the Bill and Melinda Gates Foundation, Dr. David Kaslow, Vice President of Essential Drugs and Head of Vaccine Innovation and Accessibility Center of PATH, Dr. Philip Minor, former deputy director of the British National Institute for Biological Products Control (NIBSC), and Dr. Seth Berkley, president of the Global Alliance for Vaccines and Immunization (GAVI), also sent videos to the conference to affirm China's performance and contribution in the prevention and control of the epidemic.
Dr. Anita Zaidi, Director of Vaccine Development Department of Gates Foundation, said that he was glad to see China's great efforts and investment in the research and development of the COVID-19 vaccine. Chinese researchers have established various vaccine development pipelines, which reflects the firm commitment of China's public and private sectors to jointly cope with this huge global challenge. Dr. Anita Zaidi pointed out that the Gates Foundation will support Chinese partners in meeting the challenges of the pandemic and will jointly develop and deploy vaccines, drugs and diagnostic reagents to help the world.
David Kaslow, vice president of PATH, expressed great pleasure at the establishment of the China Vaccine Innovation Alliance and affirmed the progress of China's vaccine research and development and production capacity and its contribution to global health. He said that during his work with China's vaccine partners, PATH continues to see the great potential released by China's innovative forces. China has developed of more than 50 COVID-19 vaccines candidates, some of which are advanced at an unprecedented speed. It is hoped that Chinese vaccine companies will continue to make important contributions to the global supply of safe and effective vaccines.
Dr. Philip Minor, former deputy director of NIBSC, believes that China has strong scientific research capability and strong vaccine production capacity, and has developed a large number of vaccines suitable for special purposes in the country, such as hepatitis vaccine and EV71. These capabilities can be well applied to the development of COVID-19 vaccines.
Dr. Seth Berkley, President of GAVI, first expressed warm congratulations on China's success in containing the epidemic. He pointed out that the world is now facing the biggest public health crisis in 100 years, and the greatest hope to resolve this crisis is to develop vaccines. International cooperation will be the key to fighting the epidemic. The initiatives and innovations of the China Vaccine Alliance can make great contributions to global health and safety. GAVI looks forward to continuing to cooperate with Chinese manufacturers.
On behalf of China's Strategic Alliance for Technological Innovation in the Vaccine Industry, Zhang Yuntao read out a proposal to all colleagues in the vaccine industry. The proposal emphasizes that in the face of the complicated situation of the COVID-19 epidemic, vaccine enterprises should further play their role in fighting the epidemic, better fulfill their social responsibilities, jointly promote scientific and technological research on vaccines, ensure vaccine research and development, ensure the safety of vaccine application, and fully utilize the important role of vaccines in safeguarding public health and national security. To strengthen the construction of the whole vaccine industry chain, improve the overall level and ability of the vaccine industry to serve the society; We will promote international cooperation in vaccine research and development, join hands in the global fight against the epidemic, demonstrate the responsibility of major countries, jointly build a "human health community" with the people of the world, and join hands with other countries to deal with and defeat the global epidemic as soon as possible.
Academician Wang Junzhi of National Institution for Food and Drug Control and Chief Scientist of NIBSC Dr.Javier Martin made keynote speeches on research and development of the COVID-19 vaccine. After that, the participants discussed how to explore the full potential of the vaccine alliance. Finally, Yang Xiaoming summarized the discussion and said that in the future, he would further focus on the alliance's tasks and highlight the role of vaccines.
1, China National Biotec Company Group.
2, Advaccine ( Suzhou )Biotechnology Co
3, Beijing Aimei Biological Vaccine Technology Group Co., Ltd.
4, Sinovac Biotech Co.,Ltd.
5, Beijing Minhai Biotechnology Co., Ltd
6, Chongqing Zhifei Biological Products Co., Ltd
7, Fudan University
8, Guangxi Center for Disease Prevention and Control
9, He Nan Center for Disease Prevention and Control
10, Hualan Biological Engineering, Inc.
11, Jiang Su Center for Disease Prevention and Control
12, Institute of Bioengineering, Military Medical Research Institute
13, CanSino Biologics Inc.14, Tsinghua University 15, Xiamen University 16, Stemirna Therapeutics Co., Ltd. 17, Sichuan University 18, Suzhou Abogen Biotechnology Co., Ltd. 19, Walvax Biotechnology Co., Ltd.20, Changchun Bcht Biotechnology Co.21, Institute of Virus Disease Prevention and Control of China Center for Disease Control and Prevention 22,National Institute for Communicable Disease Control and Prevention Chinese Center for Disease Control and Prevention23,National Immunization Program Chinese Center for Disease Control and Prevention
24, Institut Pasteur of Shanghai Chinese Academy of Sciences
25, National Institutes for Food and Drug Control
26, Institute of Medical Biology Chinese Academy of Medical Sciences27, Zhuhai Lifanda Biotechnology Co., Ltd.
In order to accelerate vaccine research and development in China, promote the upgrading of key industrial technologies and the quality of vaccine products, strengthen the technological reserve of China's vaccine industry, improve the ability to deal with new and emergency epidemic outbreaks and abilities of disease prevention and control, and promote the healthy development of the vaccine industry, with the promotion and support of the Ministry of Science and Technology, China National Biotec Company Group, as the supporting unit of the alliance, led the establishment of a strategic alliance for Chinese vaccine industry technology innovation strategic alliance in 2013.